Ishwaria M. Subbiah - Concepedia

Author

Ishwaria M. Subbiah

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Anai Kothari, I. M. Subbiah, I.M. Subbiah, Ishwaria M Subbiah, Ishwaria M. Subbiah, Ishwaria Mohan Subbiah, Ishwaria Subbiah, Ishwariah Subbiah

167

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center The University of Texas Health Science Center at Houston Foundation Medicine (United States)The Ohio State University University of Michigan

About

Ishwaria M. Subbiah is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	448
2	Health Sciences	2	2	32
3	Public Health	2	2	75
4	Education	1	1	17
5	Nursing	1	1	18

Ishwaria M. Subbiah

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
NCCN Guidelines® Insights: Older Adult Oncology, Version 1.2021 Efrat Dotan, Louise C. Walter, Ilene Browner, Journal of the National Comprehensive Cancer Network Palliative CareNccn Guidelines® InsightsGeriatric OncologyGeriatricsMedicine	2021	179
Validation and Development of a Modified Breast Graded Prognostic Assessment As a Tool for Survival in Patients With Breast Cancer and Brain Metastases Ishwaria M. Subbiah, Xiudong Lei, Jeffrey S. Weinberg, Journal of Clinical Oncology	2015	119
STUMP un“stumped”: anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion Vivek Subbiah, Caitlin McMahon, Shreyaskumar Patel, Journal of Hematology & Oncology	2015	99
Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents Ishwaria M. Subbiah, Daniel J. Lenihan, Apostolia M. Tsimberidou The Oncologist	2011	97
Prognostic Indicators and Treatment Outcome in 94 Cases of Fibrolamellar Hepatocellular Carcinoma Ahmed O. Kaseb, Mohamed Shama, İbrahim Halil Şahin, Oncology	2013	95
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases Vivek Subbiah, Jenny Berry, Michael Roxas, Lung Cancer Neuro-oncologyRet Inhibitor VandetanibMedicinePathologyBronchial Neoplasm	2015	68
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma Andreas Heilmann, Vivek Subbiah, Kai Wang, Oncology	2016	59
Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies Xin Shelley Wang, Samer A. Srour, Meagan Whisenant, Transplantation and Cellular Therapy	2021	57
Performance Status Restriction in Phase III Cancer Clinical Trials Joseph Abi Jaoude, Ramez Kouzy, W. Ian P. Mainwaring, Journal of the National Comprehensive Cancer Network	2020	42
Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period Hiba Dagher, Anne‐Marie Chaftari, Ishwaria M. Subbiah, eLife	2023	42

Page 1